Skip to main content

Enforcement & Compliance

Health Sciences Authority (HSA) · Health Products Act (Cap. 122D) · HP(MD) Regulations 2010

Overview

The Health Sciences Authority (HSA) has comprehensive enforcement powers under the Health Products Act (Cap. 122D) to ensure medical devices on the Singapore market are registered, licensed, safe, and compliant. Enforcement covers both product-level compliance (registration, labelling, performance) and company-level compliance (dealer's licence obligations, QMS, GDP, post-market).

Compliance Monitoring Activities

HSA monitors compliance through:

ActivityDescription
Market surveillanceSampling and testing of devices available in Singapore
Dealer's licence auditsPeriodic audits of licensees' QMS and GDP practices by HSA-recognised Medical Device Auditors
SHARE portal monitoringReview of registration status, change notifications, and adverse event reports
Complaint investigationInvestigation of healthcare professional and patient reports about non-compliant devices
Import monitoringCoordination with Singapore Customs to identify unregistered imports
Post-market signal reviewAssessment of international safety alerts and overseas FSCAs for Singapore-impact

Enforcement Actions Available to HSA

ActionBasisDescription
Warning letterHPA s.31Written notice of non-compliance; requires CAPA within a specified timeframe
Recall directionHPA s.71Direction to recall a product from the market
Suspension of registrationHPA s.27–30Temporary suspension of product registration pending investigation
Cancellation of registrationHPA s.27–30Permanent removal from the Singapore Medical Device Register
Suspension of dealer's licenceHPA s.16–22Temporary suspension of authority to manufacture, import, or wholesale
Cancellation of dealer's licenceHPA s.16–22Permanent withdrawal of licence
Seizure and forfeitureHPA s.66–70Physical seizure of non-compliant or unregistered devices
ProsecutionHPA Part IXCriminal prosecution for serious offences
Civil financial penaltyHPA s.74Monetary penalties for regulatory violations

Offences and Penalties

The Health Products Act creates specific offences for medical device non-compliance:

OffenceMaximum Penalty
Supply of unregistered deviceFine up to S$50,000 and/or imprisonment up to 2 years
Supply without a dealer's licenceFine up to S$50,000 and/or imprisonment up to 2 years
Non-compliant labellingFine up to S$20,000
Failure to report adverse eventFine up to S$20,000
Failure to report FSCAFine up to S$20,000
Failure to maintain distribution recordsFine up to S$20,000
Obstruction of HSA inspectorFine up to S$20,000

Penalties for corporate offences may be higher. Directors and senior officers of a company may also be personally liable for offences committed by the company.

SG-Unique

Singapore's dual-obligation model means both the product and the company can face simultaneous enforcement action — product registration can be suspended while the company's dealer's licence is also reviewed.

Registration Suspension and Cancellation

HSA may suspend or cancel a product's registration in the Singapore Medical Device Register (SMDR) where:

  • New safety information indicates an unacceptable benefit-risk profile
  • The registrant fails to submit required post-market information
  • The device is found to be mislabelled or falsely described
  • An international regulator (TGA, FDA, EU, Health Canada, MHLW) has suspended or withdrawn approval

Following suspension, the registrant must cease supply and cooperate with any HSA investigation. Recall of already-supplied units may be required.

Inspector Powers

Under the Health Products Act, HSA-authorised inspectors may:

  • Enter and inspect licensed premises at any reasonable time
  • Inspect, examine, and seize goods
  • Request records, documents, and samples
  • Require explanations and information from persons on the premises
  • Seal or impound equipment used in commission of an offence

Obstruction of an inspector is a criminal offence.

Responding to HSA Enforcement Actions

If HSA issues an enforcement notice:

  1. Do not ignore it — respond in writing within the specified timeframe
  2. Engage a Singapore-experienced regulatory consultant or legal advisor
  3. Cease supply of any affected products unless instructed otherwise
  4. Prepare a CAPA response addressing all cited deficiencies with objective evidence
  5. Do not resume supply without written HSA clearance
  6. Document all communications with HSA throughout the process

Voluntary Disclosure

Companies that identify compliance issues and voluntarily disclose them to HSA before HSA identifies them independently are generally treated more favourably. HSA's approach encourages voluntary compliance and early reporting of safety signals. Proactive engagement through the SHARE portal's adverse event reporting function is the correct mechanism.

Official Sources